Screening PSA levels at aged 65-69 may inform the decision to continue or discontinue prostate cancer screening after age 70 years, regardless of patient race and ethnicity. The absolute risks of ...
Hormonal therapies are effective for recurrent and advanced prostate cancer, with PSA levels crucial for risk stratification. Combination hormone therapy is advised for metastatic prostate cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results